|Articles|February 11, 2021
- Pharmaceutical Executive-02-01-2021
- Volume 41
- Issue 2
Pharmaceutical Executive, February 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive February 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
Pharm Exec at 40almost 5 years ago
A Vision of a Fairer Worldalmost 5 years ago
Coupon-Program Pivot: Meeting New Legal, Operational Hurdlesalmost 5 years ago
Digital-Communication Check: Insights Learned During Lockdownalmost 5 years ago
The Best and the Worst on Display in Vaccine Effortalmost 5 years ago
The Fight for Orphan Drug Research Reform in Europealmost 5 years ago
A ‘Golden Year’ for UK Life Sciences Sector?almost 5 years ago
A Generational Opportunity for Talent Pipeline Developmentalmost 5 years ago
Emotional Intelligence Can Help Lead Pharma Through Tough TimesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
3
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
4
FDA Sends Decision Letter to Vanda Pharmaceuticals for NDA of Hetlioz
5

